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Leishmania is associated with a broad spectrum of diseases, ranging from simple
cutaneous to invasive visceral leishmaniasis. Here, the sequences of ten cysteine
proteases of types A, B and C of Leishmania major were obtained from GeneDB
database. Prediction of MHC class I epitopes of these cysteine proteases was per-
formed by NetCTL program version 1.2. In addition, by using BcePred server,
different structural properties of the proteins were predicted to find out their po-
tential B cell epitopes. According to this computational analysis, nine regions were
predicted as B cell epitopes. The results provide useful information for designing
peptide-based vaccines.
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Introduction
Leishmania (Order: Kinetoplastida, Family: Try-
panasomatidae) is an obligate intracellular parasite
responsible for a broad spectrum of diseases, ranging
from simple cutaneous to invasive visceral leishmania-
sis (1 ). Protozoan parasites of the genus Leishmania
present two forms in their life cycle: promastigote,
which multiplies in the mid gut of the sand fly vector,
and amastigote, the obligate intracellular form that
lives within phagolysosomes of the vertebrate host
(2 , 3 ). Three major types of leishmaniasis, namely
cutaneous, mucocutaneous and visceral, occur in hu-
mans depending on the species of Leishmania. Infec-
tion by species such as L. major, L. tropica and L.
mexicana may cause localized cutaneous lesions, re-
sulting in lifelong immunity. Infection by L. brazilien-
sis and L. panamensis initially presents as cutaneous
lesions that may then spread or metastasize causing
mucocutaneous lesions. Infection by L. donovani, L.
infantum and L. chagasi may result in a chronic dis-
seminating visceral disease in the liver and spleen (4 ).
It has been recognized for many years that pro-
teases of pathogenic organisms may modulate the
host’s defense mechanisms (5 ). Proteases are grouped
into clans and families on the basis of the architec-
ture of their catalytic dyad or triad (6 ). Each clan is
identified with two letters, the first representing the
catalytic type of the families included in the clan. L.
major has cysteine proteases (CPs) of eight families
within clan CA. Family C1 contains CPA and CPB,
which are both cathepsin L-like in terms of primary
amino acid sequence, and CPC, which is cathepsin B-
like. CPB is unusual in that it has a 100-amino acid
C-terminal extension in comparison with most CPs of
the group, and exists as multiple isoenzymes, which
are encoded by a tandem array of similar CPB genes
located in a single locus (the arrays comprise eight
genes in L. major). The CPBs of L. mexicana are
stage-regulated and the isoforms present differences
in their substrate specificity and catalytic properties
(7 ).
Although the exact roles of CPs in Leishmania
pathogenesis are unclear, it has been demonstrated
that Leishmania cannot grow within macrophages in
the presence of CP inhibitors (8 ). These observa-
tions provide evidence of the importance of these
molecules in the survival of both promastigote and
amastigote forms of these parasites (9 ). Despite try-
panosomatid CPs may be instrumental in modulat-
ing the host’s immune response to favor parasite sur-
vival and proliferation, they are themselves immuno-
genic. L. mexicana CP is a T cell immunogen, re-
sulting in the development of potentially protective
Thl cell lines (10 ). This finding suggests that the
CP itself is a vaccine candidate and that homolo-
gous enzymes in other species may also be so. A CP
of L. pifanoi, however, provided rather little protec-
tion for the host against infection with the parasite
(11 ), although more recently a similar L. amazonensis
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CP provided some protection against subsequent chal-
lenge, apparently through inducing a Thl-associated
response (12 ). These differing results presumably
reflect the complexity of the immune response to the
active parasite enzymes and how the response may
be determined by the precise immunization condi-
tions. It is therefore encouraging that a CP-rich frac-
tion of L. major was shown to be a strong inducer
of a primed human immune response and may have
protective function (13 ). These observations suggest
that trypanosomatid CPs have potential as vaccines
although attempts to exploit them are really just be-
ginning (14 , 15 ). In addition, it has also been proven
that infected dendritic cells are the critical antigen-
presenting cells responsible for T cell priming in Leish-
mania infections. Amastigotes, but not the infectious
promastigotes, are the main targets for phagocytosis
activity of dendritic cells (16 , 17 ).
A key step in the design of subunit vaccines is
the identification of epitopes from overlapping syn-
thetic peptides. This method decreases the possi-
bility of missed epitopes, but lots of peptides need
to be synthesized at a high cost. New develop-
ments in immunoinformatics and other computational
methodologies, combined with the broad versatility
in the design and synthesis of genetic (DNA) vac-
cines, underlay new strategies for the novel design
of antigen-specific, epitope-based vaccines against
many pathogens that currently have proven refrac-
tive to conventional vaccine therapy (18 ). Epitopes
are selected by prediction with software, which saves
the expense of synthetic peptides and working time
(19 , 20 ).
Basically, the recognition of antigenic epitopes by
the immune system, either small discrete T cell epi-
topes or large conformational epitopes recognized by
B cells and soluble antibodies, is the key molecu-
lar event at the heart of the immune response to
pathogens (21 ). The objective of this bioinformatics-
based study is to enhance the optimal selection of epi-
topic regions of clan CA, C1 family of cysteine pro-
teases as potential targets of immune response. Con-
sensus sequence methodology was used to identify se-
quences of 9 amino acids or longer with complete con-
servation in 80% or more of C1 families of cysteine
proteases. These conserved sequences were further
analyzed to identify targets for candidate epitope-
based T cell vaccine formulations against L. major.
Furthermore, concerning the activation of human hu-
moral immunity by leishmaniasis, B cell epitopes were
also predicted based on propensity scales for each of
the 20 amino acids. Utilizing bioinformatics servers
for vaccine candidates is a time-saving approach that
could significantly help to increase our information
about various aspects of pathogens in molecular biol-
ogy. These theoretical predictions can then be tested
by using experimental and complementary methods.
Results
Prediction of MHC class I binding pep-
tides
For the prediction of major histocompatibility com-
plex (MHC) class I binding peptides of C1 family of
cysteine proteases, one sequence for each of the cys-
teine proteases A, B and C was selected. In the case
of CPB, due to the high similarity between these cys-
teine proteases, only one out of eight sequences was
chosen (LmjF08.1050). This sequence is a good can-
didate of CPB because of the complete identity of its
sequence with the consensus sequence of CPB. All
overlapping nonamer peptides were generated from
this dataset and were screened for potential T cell
antigens using the NetCTL algorithm, from which 716
peptides were short-listed. Most of the peptides were
found to exhibit mono-supertype specificity, meaning
that they bind to a single supertype. Some of them,
however, appeared to bind to multiple supertypes; the
highest number of supertypes a given nonamer could
bind is 5 out of the 12 supertypes tested. In fact, out
of the 716 human leukocyte antigen (HLA)-binding
nonamers, one peptide binds to 5 supertypes, 4 bind
to 4 supertypes, 9 bind to 3 supertypes and 44 bind
to 2 supertypes. Sequences of binding peptides to the
4 and 5 supertypes and the name of proteins they
belong to are summarized in Table 1.
Knowing the number of binding peptides of each
of the analyzed proteins is important, considering the
polymorphic nature of HLA and its diversity in pop-
ulations of different geographical regions. Therefore,
Table 1 Number of supertypes that a given
nonamer could bind
Peptide sequence Protein No. of binding
to the supertypes
339-HVSQSPTPG-347 CPB 5
9-FAIVVTILF-17 CPA 4
270-FMSYHSGVL-278 CPB 4
42-AEVNSKAKG-50 CPC 4
258-LTMQVYSDF-266 CPC 4
88 Genomics Proteomics Bioinformatics Vol. 7 No. 3 September 2009
Saffari and Mohabatkar
a good T cell antigen should have peptides recognized
by many HLA alleles. The analysis revealed that CPB
has the maximum number of binding peptides, fol-
lowed by CPC and CPA, respectively (Table 2).
For short-listing potential vaccine candidates, it is
important to analyze the binding profiles from a su-
pertype perspective. Of the 12 supertypes studied,
the largest number of nonamers was found to be rec-
ognized by the allele B62 (53), followed by B58 (38),
A2 (36), A24 (24), A1, B8 and B39 (21), B44 (20),
A3 and B7 (19), B27 (17) and A26 (15), as illustrated
in Figure 1.
The score with which a peptide binds to HLA
ranges from 0.75 to 3.1949. In general, the bind-
ing score of CPC peptides to A1 locus supertypes is
higher compared with CPB, CPA and other super-
types (Table 3).
Putative promiscuous T cell epitopes may be local-
ized in clusters, as reported in studies of HIV-1 (22–
25 ), the outer membrane of Chlamydia trachomatis
Table 2 Generated and binding peptides from selected cysteine proteases
Systematic name Protein Features No. of No. of No. of Percent of No. of binding
in GeneDB amino generated binding binding peptides with
acid peptides peptides peptides score >1.5
LmjF19.1420 CPA cathepsin L-like 354 346 91 26.3% 8
LmjF08.1050 CPB cathepsin L-like 348 340 103 30.3% 9
LmjF29.0820 CPC cathepsin B-like 340 332 96 28.9% 15
Table 3 Features of binding peptides with high scores
No. Protein Supertype Peptide Score
1 CPC A1 52-WTASADNGY-60 3.1949
2 CPC A1 308-NTDWGDKGY-316 2.6687
3 CPC A1 19-LATTVSGLY-27 2.3211
4 CPA A1 77-NTHNPHAHY-85 2.0979
5 CPC A1 131-AVEAISDRY-139 1.9722
6 CPC A1 76-VTDMSTEAV-84 1.9262
7 CPC A24 204-KYPPCPSTI-212 1.9244
8 CPC B44 279-GEFLGGHAV-287 1.9117
9 CPC A26 52-WTASADNGY-60 1.8531
10 CPC A1 224-RSEMDLVKY-232 1.8397
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Figure 1 Observed variation in the binding of predicted peptides to the 12 different HLA class I supertypes studied.
The figure depicts the proportion of binding peptides to individual supertypes.
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(26 ), and among others (27 , 28 ). The clusters are
also ideal for developing epitope-based vaccines be-
cause they contain multiple promiscuous epitopes.
The number of immunogenic hotspots for CPA, CPB
and CPC is 4, 5 and 0, respectively, as shown in
Table 4.
The identification of conserved sequences is very
important to design peptide vaccines, because vac-
cines that are developed on the basis of the con-
served segments among candidate proteins can be
used against a large majority of pathogen’s variants.
In Figure 2, three segments (I, II and III) with iden-
tity ≥90% and have ≥9 amino acids in length are
shown as conserved regions. Obviously the epitopes
predicted in these regions are very significant. For
immunological applications, a minimum conserved se-
quence length of 9 amino acids is required because this
represents the typical length of peptides that bind
to HLA molecules (29 ). The features of potential
epitopes located in conserved regions with maximum
scores are summarized in Table 5.
B cell epitope prediction
Before the prediction of B cell epitope of CPB
(LmjF08.1050), signal peptide of this protein pre-
dicted by SignalP 3.0 hidden Markov model (HMM)
(signal peptide probability 0.999, signal anchor prob-
ability 0.001, with cleavage site probability 0.760 be-
tween residues 27 and 28) was excluded. Hydrophilic-
ity, flexibility, accessibility, turns, exposed surface,
polarity and antigenic propensity scales were applied
to predict B cell epitopes. These parameters were cor-
related with the location of continuous epitopes. As a
result, 9 regions were predicted to be B cell epitopes
(Figure 2).
Discussion
The aim of this investigation was to apply bioinfor-
matics methods to study the B and T cell epitopic
sites of C1 family cysteine proteases of L. major.
To help the development of vaccines, understanding
the structural basis for the cell-mediated immune re-
sponse is necessary (30 ). The perfect bioinformatics
prediction of T cell epitopes can to a great extent re-
duce the experimental cost in candidate epitope iden-
tification (31 ).
In the present study, NetCTL program has been
used to predict MHC class I of cysteine proteases A, B
and C of L. major (32 ). CP proteins are immunogenic
and are potential vaccine candidates. Efficient pro-
cessing and presentation of vaccine antigens by class
I and/or class II MHC are essential for a good T cell
response. Since humans carry only a limited number
of co-dominant HLA alleles in their genome (2 each
for A, B and C loci), out of hundreds of polymorphic
alleles present in the population, it becomes impor-
tant that a candidate vaccine must generate peptides
that bind to a wide range of HLA molecules to provide
good population coverage.
Table 4 Features of immunogenic hotspots of CPA and CPB
CP Supertype Position Score Threshold Length
CPA A2 1–39 57.38 55 39
A2 174–224 56.20 55 51
A3 61–93 45.46 45 33
A3 230–279 45.21 45 50
CPB A2 1–38 55.65 55 38
A2 188–221 55.04 55 34
A3 18–138 46.51 45 121
A3 151–193 45.19 45 43
A3 228–270 45.42 45 43
Table 5 Epitopes with highest scores located in conserved regions
Conserved region Epitope sequence Supertype Score CP
I 133-REKGAVTPV-141 B44 1.2763 CPB
II 148-GMCGSCWAF-156 B62 1.2696 CPA
III 283-GEQLNHGVL-291 B44 1.7068 CPB
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Figure 2 Alignment of C1 family of clan CA of cysteine proteases. Gray rectangular under each sequence is the
corresponding regions of that sequence, which is determined with Pfam database as conserved sequences. Sequences
shown in boxes are predicted B cell epitopes of CPB (LmjF08.1050). Regions that have identity ≥90% are shown with
Roman numerals. The most conserved residues that appear in the consensus sequence are indicated by “*”.
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In this work we found that generated peptides
bind in larger numbers to B supertypes. However,
almost all of the peptides with the highest binding
score belong to CPC. In other words, CPC is the
major source of peptides that bind to HLA loci with
more affinity. These observations suggest that greater
emphasis must be placed on cytotoxic T lymphocyte
(CTL) response generated by the presentation of anti-
gen by B alleles and should design epitope-based vac-
cine directed towards these HLA.
T cell epitopes specific to multiple HLA super-
types are advantageous for vaccine design because
they effectively increase the number of epitopes to
which an individual can respond, and provide much
more extensive coverage of the population (33 ). The
peptides binding to more than one HLA are termed
promiscuous and such peptides are of prime interest
for vaccine design because of their relevance in cover-
age of higher proportions of human populations. In
silico approaches would help to predict some of the
HLA-binding motifs, which could act as promiscu-
ous epitopes (34 ). Most of the generated nonameric
peptides in this work are mono-allelic binders. To
cover majority of the population, it is essential to have
vaccine candidates that have multi-binding behavior.
Consequently, peptides with the binding ability of ≥4
supertypes were taken as promiscuous epitopes. Note
that each supertype consists of multiple HLA alleles,
and peptides that can bind to ≥4 supertypes have a
great potentiality to activate the most proportion of
T cell population.
It is generally recognized that conserved pro-
tein sequences represent important functional do-
mains (35 ), for which mutations would be detri-
mental to the survival of the pathogen. The func-
tions of conserved sequences can be elucidated by
databases that comprise data on protein families, do-
mains and functional sites, such as the Pfam database
(www.sanger.ac.uk/Software/Pfam) (36 ). In Figure
2, in addition to the ClustalW consensus sequence,
the results of the Pfam database and the highly con-
served regions that have ≥9 amino acids in length
have also been shown. It is clear that the predicted
epitopes located in the conserved segments have more
validity.
Eventually, identification of proteins with pep-
tides binding to larger number of alleles, assessment
of alleles or supertypes of MHC that bind large num-
ber of peptides than others have great importance in
determining epitopes as a candidate vaccine. In addi-
tion, allelic variation in binding affinity, immunologi-
cal hotspots, HLA distribution analysis and similarity
of epitopes to the self proteins play a key role in iden-
tification of these epitopes (34–36 ).
In proteins, turns are located on the surface; these
parts are accessible and hydrophilic but the core re-
gions are mostly devoid of water molecules (37 ). Anti-
genic determinants lie in regions that are hydrophilic,
exposed and polar, while accessibility and flexibility
of these segments are high. This has led to the rules
that would allow the position of B cell epitopes to be
predicted from these features of the protein sequence
(37 , 38 ).
In conclusion, recognizing epitopes on proteins is
essential for developing synthetic vaccines and can
facilitate immunotherapy of leishmaniasis and many
other infectious diseases. In the present work, employ-
ing a bioinformatics approach, a set of peptides has
been identified, which can be used in either a nat-
ural or a synthetic vaccine cocktail. This approach
could be extended to the entire proteome of L. ma-
jor to identify newer sets of potentially antigenic pro-
teins and yet reducing the number of T and B cell
antigens for experimental verification. These kinds of
researches can be applied for omitting non-functional
sequences of proteins, which would help in designing
new immunological methods.
Materials and Methods
Amino acid sequences
The sequences of ten cysteine proteases (clan CA,
family C1) of L. major were obtained from GeneDB
database (www.genedb.org) (39 ). Sequences in-
cluded one CPA (Systematic ID: LmjF19.1420), one
CPC (LmjF29.0820) and eight CPBs (LmjF08.1010,
LmjF08.1020, LmjF08.1030, LmjF08.1040, LmjF08.
1050, LmjF08.1060, LmjF08.1070 and LmjF08.1080).
Prediction of MHC class I binding pep-
tides
NetCTL program version 1.2 (http://www.cbs.dtu.dk/
services/NetCTL/) (40 ) predicts peptides restricted
to 12 HLA class I supertypes (A1, A2, A3, A24,
A26, B7, B8, B27, B39, B44, B58 and B62), inte-
grated with predictions of HLA binding, proteasomal
C-terminal cleavage and transport efficiency by the
transporter associated with antigen processing (TAP)
molecules. HLA binding and proteasomal cleavage
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predictions were performed by an artificial neural net-
works (ANN) method and TAP transport efficiency
was predicted using a weight matrix method. The
parameters used for NetCTL prediction were: 0.15
weight on C terminal cleavage, 0.05 weight on TAP
transport efficiency, and 0.75 threshold for HLA su-
pertype binding. The final scores are the predicted
MHC class I affinities in form of −logIC50 and IC50
values.
B cell epitope prediction
All prediction calculations were based on propensity
scales for each of the 20 amino acids. Sequence of
each protein was read as a moving window. In or-
der to compare the profiles obtained by different
methods, various scales were normalized where the
original values of each scale were set between +3
and −3. Hydrophilicity (41 ), flexibility (42 ), ac-
cessibility (43 ), turns (44 ), exposed surface (45 ),
polarity (46 ) and antigenic propensity (47 ) scales
were applied to predict B cell epitopes by BcePred
server (http://www.imtech.res.in/raghava/bcepred)
with default threshold.
Signal peptide prediction
Due to the elimination of signal peptides of CPBs
before secretion to the outer space of the infected
cells, this region must be excluded from the entire
sequence of the protein for exerting the prediction
analysis on it. Signal peptide prediction was achieved
using SignalP 3.0 HMM (http://www.cbs.dtu.dk/
services/SignalP-3.0/) (48 ).
Immunogenic hotspot prediction
Putative promiscuous T cell epitopes may be localized
in clusters that are also ideal for developing epitope-
based vaccines because they contain multiple promis-
cuous epitopes. For determining the immunogenic
hotspots, MULTIPRED server (http://antigen.i2r.a-
star.edu.sg/multipred/) (49 ) was utilized.
Alignment
Sequences were aligned using ClustalW program (50 )
from the BioEdit v5.0.9 package (51 ).
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